Pre-meeting Survey
Please complete this short survey to help us better understand local physicians’ perception and adoption of genetic testing and the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC).
Genetic testing perception and adoption
1. What is your perception regarding the awareness of associating BRCA with prostate cancer amongst local physicians? [on a scale of 1–5, with 5 being the highest awareness]
12345
1
2
3
4
5
2. How often do you talk to patients about BRCA testing in prostate cancer and its therapeutic implications? [on a scale of 1–5, with 5 being the most frequent, i.e. in all eligible patients]
12345
1
2
3
4
5
3. To what extent do you agree with the following statement? ‘Genetic testing results are essential for me to guide patient counselling’ [on a scale of 1–5, with 5 representing the highest level of agreement]
12345
1
2
3
4
5
4. How likely are you to incorporate genetic testing for prostate cancer in your clinical practice? [on a scale of 1-5, 5 it is part of the standard of care]
12345
1
2
3
4
5
5. What are the difficulties experienced/anticipated when conducting genetic testing? [you may select more than one]
6. At what stage of the patient’s journey should BRCA testing best be conducted?
Current unmet needs and positioning of PARP inhibitors
7. From a physician’s perspective, how would you rank the importance of these treatment considerations for patients with mCRPC?
(1 = most important and 6 = least important)
123456
Treatment with better efficacy
1
2
3
4
5
6
Treatment with better safety
1
2
3
4
5
6
Treatment monitoring
1
2
3
4
5
6
Cheaper drug cost
1
2
3
4
5
6
Quality of life
1
2
3
4
5
6
Ease of administration
1
2
3
4
5
6
8. Please rank the importance of these treatment gaps in managing your patients with mCRPC.
(1 = most important and 5 = least important)
12345
Efficacy
1
2
3
4
5
Safety
1
2
3
4
5
Affordability
1
2
3
4
5
Ease of administration
1
2
3
4
5
Quality of life
1
2
3
4
5
9. How would you rate your understanding of PARP inhibitors in mCRPC? For e.g., familiarity with efficacy data, safety data, etc.
Extremely familiarVery familiarModerately familiarSlightly familiarNot familiar at all
Extremely familiar
Very familiar
Moderately familiar
Slightly familiar
Not familiar at all
10. For which patients with mCRPC would you consider initiating PARP inhibitors?
(Select all that apply)
Thank you very much for your participation!

HK-8637